COMPANY OVERVIEW
Likang Life Sciences is a biotechnology company focused on the development and clinical translation of personalized cancer immunotherapies. We integrate AI-assisted neoantigen identification and high-throughput sequencing with multiple therapeutic modalities, including mRNA and cell-based platforms, to advance a diverse portfolio of personalized cancer immunotherapy programs. We aim to explore more targeted therapeutic strategies and precision immunotherapy.
LIKANG LIFE SCIENCES｜FOUNDED IN 2017
OUR HISTORY
Beginning with AI-powered neoantigen discovery, TCR discovery, mRNA sequence design and TCE drug design, we continues to advance its technology platforms, product pipeline, and clinical development in China and the United States.
2017
Beijing, China
2018
Proprietary AI-powered platform for tumor neoantigen analysis
MAR, 2023
China’s National Medical Products Administration
FEB 2025
Cleared to begin clinical trials in the United States
APR 2025
Covering 11 solid tumor indications
2017
Beijing, China
2018
Proprietary AI-powered platform for tumor neoantigen analysis
MAR, 2023
China’s National Medical Products Administration
FEB 2025
Cleared to begin clinical trials in the United States
APR 2025
Covering 11 solid tumor indications
Dr. Chen earned his bachelor’s degree from Beijing Institute of Technology and his Ph.D. from the Institute of Biophysics, Chinese Academy of Sciences, followed by postdoctoral research in clinical medicine at Peking University Cancer Hospital. His work focuses on tumor neoantigens, T-cell immunity, and the development and clinical translation of personalized cancer immunotherapies.
Founder, Chairman and CEO
